Clinical trial
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 Injection in Patients With Chronic Spontaneous Urticaria
NCT07875426 is registered in ClinicalTrials.gov with Akeso as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 Injection in Patients With Chronic Spontaneous Urticaria
- Lead sponsor
- Akeso
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 21, 2026
- Completion date
- February 5, 2029
- Enrollment
- 201 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
chronic spontaneous urticaria